These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36515370)

  • 1. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption.
    Morton E; Sakai K; Ashtari A; Pleet M; Michalak EE; Woolley J
    J Psychopharmacol; 2023 Jan; 37(1):49-60. PubMed ID: 36515370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "A sense of the bigger picture:" A qualitative analysis of follow-up interviews with people with bipolar disorder who self-reported psilocybin use.
    DellaCrosse M; Pleet M; Morton E; Ashtari A; Sakai K; Woolley J; Michalak E
    PLoS One; 2022; 17(12):e0279073. PubMed ID: 36516137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.
    Kopra EI; Ferris JA; Winstock AR; Young AH; Rucker JJ
    J Psychopharmacol; 2022 Aug; 36(8):965-973. PubMed ID: 35388724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.
    Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1268-1278. PubMed ID: 27578767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.
    Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR
    J Psychopharmacol; 2016 Dec; 30(12):1279-1295. PubMed ID: 27856683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020.
    Kopra EI; Ferris JA; Winstock AR; Kuypers KP; Young AH; Rucker JJ
    J Psychopharmacol; 2023 Jul; 37(7):733-748. PubMed ID: 36876583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perceived harm, motivations for use and subjective experiences of recreational psychedelic 'magic' mushroom use.
    Roberts CA; Osborne-Miller I; Cole J; Gage SH; Christiansen P
    J Psychopharmacol; 2020 Sep; 34(9):999-1007. PubMed ID: 32674668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magic Mushroom Use: A Qualitative Interview Study of Post-Trip Impacts and Strategies for Optimizing Experiences.
    Shaw L; Rea K; Lachowsky NJ; Roth EA
    J Psychoactive Drugs; 2023; 55(2):151-158. PubMed ID: 35315749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Psychoactive mushrooms - an update].
    Supprian T; Frey U; Supprian R; Rösler M; Wanke K
    Fortschr Neurol Psychiatr; 2001 Dec; 69(12):597-602. PubMed ID: 11753749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unpredictable Behavior Under the Influence of "Magic Mushrooms": A Case Report and Review of the Literature.
    Honyiglo E; Franchi A; Cartiser N; Bottinelli C; Advenier AS; Bévalot F; Fanton L
    J Forensic Sci; 2019 Jul; 64(4):1266-1270. PubMed ID: 30548541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-response relationships of psilocybin-induced subjective experiences in humans.
    Hirschfeld T; Schmidt TT
    J Psychopharmacol; 2021 Apr; 35(4):384-397. PubMed ID: 33663259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.
    Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS
    Am J Ther; 2024 Mar-Apr 01; 31(2):e121-e132. PubMed ID: 38518269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Automutilation after consumption of hallucinogenic mushrooms].
    Attema-de Jonge ME; Portier CB; Franssen EJ
    Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2869-72. PubMed ID: 18257429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term Amelioration of OCD Symptoms in a Patient with Chronic Consumption of Psilocybin-containing Mushrooms.
    Lugo-Radillo A; Cortes-Lopez JL
    J Psychoactive Drugs; 2021; 53(2):146-148. PubMed ID: 33225874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of smartphone apps in bipolar disorder: An international web-based survey of feature preferences and privacy concerns.
    Morton E; Nicholas J; Lapadat L; O'Brien HL; Barnes SJ; Poh C; Michalak EE
    J Affect Disord; 2021 Dec; 295():1102-1109. PubMed ID: 34706421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marketing pitches of 'magic mushrooms' and 'psychedelics' mask that psychotomimetics use exposes those vulnerable to serious adverse effects.
    Braillon A; Naudet F
    J Psychopharmacol; 2023 Jul; 37(7):749-750. PubMed ID: 37132539
    [No Abstract]   [Full Text] [Related]  

  • 20. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.